Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Table 6

Adverse reaction rates after treatment (n (%)).

Characteristic	GEM-IRE group (n = 30)	IRE group (n = 30)	value
Hemoglobin reduction	22 (73.3)	15 (50.0)	0.110
Leukocyte reduction	4 (13.3)	2 (6.7)	0.671
Neutropenia	2 (6.7)	3 (10.0)	1.000
Thrombocytopenia	15 (50.0)	12 (40.0)	0.604
Transient elevation of myocardial enzyme	14 (46.7)	8 (26.7)	0.180
Proteinuria	1 (3.3)	0 (0.0)	1.000
Hypokalemia	1 (3.3)	2 (6.7)	1.000
Pancreatitis	1 (3.3)	1 (3.3)	1.000
Bleeding from duodenal ulcer	1 (3.3)	0 (0.0)	1.000
Fever	6 (20.0)	4 (13.3)	0.731
Diarrhea	1 (3.3)	0 (0.0)	1.000
Nausea and vomiting	6 (20.0)	3 (10.0)	0.472
Infection	2 (6.7)	1 (3.3)	1.000
Abdominal pain	5 (16.7)	7 (23.3)	0.748
Loss of appetite and/or reduced intake	7 (23.3)	2 (6.7)	0.145
Mild ascites	15 (50.0)	12 (40.0)	0.604
Mild pleural effusion	5 (16.7)	3 (10.0)	0.706
Abdominal distention	8 (26.7)	4 (13.3)	0.333